News | September 19, 2014

Interim analysis of triple-blind, parallel-controlled trial proves intraoperative MRI more effective than conventional neurosurgery for certain brain tumors

Imris Visius iMRI

The Imris Visius iMRI at Huashan Hospital in Shanghai, China, provides neurosurgeons high-quality MR images during surgery which results in more complete brain tumor removal in patients. (CNW Group/Imris Inc.)


September 19, 2014 — Imris Inc. announced that a recently published article in the journal Neurosurgery is the highest-level clinical evidence to show that the use of Visius intraoperative magnetic resonance imaging (iMRI) in brain tumor surgery results in complete tumor removal in more patients with glioma tumors.

Led by Dr. Jin-song Wu, the neurosurgical team at Huashan Hospital at Fudan University in Shanghai, China, conducted the study and wrote the interim analysis article that was published in August. Wu and the clinical team were honored with the Journal of Neuro-Oncology Award at the Congress of Neurological Surgeons (CNS) Annual Meeting in October 2013 for their study design and abstract.

The prospective, parallel, randomized, triple-blind controlled trial design provides the most objective data and therefore highest level evidence to date of the value of iMRI in treating both low and high-grade gliomas. The early results reinforce that high-field iMRI-guided surgery is more effective in achieving complete resection than conventional neuronavigation-guided surgery. Other published studies on high-field iMRI have been mainly retrospective.

"iMRI is a practical and valuable asset to increasing the extent of resection for cerebral gliomas, with a specific significant influence for low grade gliomas," Wu said. "With trends to statistical significance, these early results are the highest level of iMRI evidence for glioma surgery now available. This leads to more improved overall survivability and quality of life than using conventional neuronavigation."

The low-grade glioma (LGG) subgroup patients who were treated in a Visius Surgical Theatre using iMRI had a statistically significant complete resection rate of 82 percent compared to 43 percent for the control group of conventional surgery patients. For the high-grade glioma (HGG) patients, 91 percent of those treated with iMRI had complete resection compared to 73 percent for the control group. These results are confirmed by volumetric analysis. The LGG subgroup met the endpoint early and that arm of the study stopped enrolling additional patients. The study continues for HGG patients.

The Imris Visius Surgical Theatre with iMRI at Huashan Hospital provides neurosurgeons high-quality MR images during surgery to see the area of the brain they are operating on in exquisite detail, see tumor size and shape, and distinguish between healthy and unhealthy tissue more easily. The surgeon can take images before completing the surgery and check if additional tumor or abnormal tissue removal is needed to reduce risk of re-operation.

Unlike other iMRI systems, the Imris scanner moves between two adjoining rooms - one intended for surgery and the other for diagnostic scanning - on ceiling-mounted rails to the patient so the surgical team can maintain optimal surgical positioning, access and techniques without moving the patient.

One of five Visius Surgical Theatre installations in China, more than 1,000 patient procedures have been completed using the Fudan University iMRI since its installation in Sept. 2010.

For more information: journals.lww.com/neurosurgery/Citation/2014/08001/3_0_T_Intraoperative_Magnetic_Resonance.31.aspx.


Related Content

Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | HIMSS

March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) ...

Time March 03, 2026
arrow
News

Feb. 26, 2026 — GE HealthCare and UCSF Health have announced a 10-year Care Alliance collaboration focused on ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | Contrast Media

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

Time February 24, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | Radiology Education

Jan. 22, 2026—The American Roentgen Ray Society (ARRS) will host a live virtual symposium, "Medical Imaging for ...

Time January 28, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
News | Stroke

Dec. 12, 2025 — Hyperfine, Inc. has announced that it has received FDA clearance for a new multi-direction diffusion ...

Time December 15, 2025
arrow
Subscribe Now